Incurin is a veterinary medicine used for the treatment of hormone-dependent urinary incontinence resulting from sphincter mechanism incompetence (SMI) in ovariohysterectomised bitches (i.e. in dogs having had the ovaries and uterus removed surgically). Incurin contains the active substance estriol.
Incurin : EPAR - Summary for the public (PDF/117.79 KB)
First published: 06/06/2008
Last updated: 24/02/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Intervet International BV
|Date of issue of marketing authorisation valid throughout the European Union||
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
30/08/2014 Incurin - EMEA/V/C/000047 - IA/0006/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Sex hormones and modulators of the genital system
The treatment of hormone-dependent urinary incontinence due to sphincter mechanism incompetence in ovariohysterectomised bitches.